Protalix BioTherapeutics (PLX) Competitors $1.54 +0.05 (+3.00%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 07/3/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLX vs. ORGO, PRTC, KMDA, ORKA, ATAI, RAPP, RGNX, ERAS, ABVX, and FULCShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Organogenesis (ORGO), PureTech Health (PRTC), Kamada (KMDA), Oruka Therapeutics (ORKA), atai Life Sciences (ATAI), Rapport Therapeutics (RAPP), REGENXBIO (RGNX), Erasca (ERAS), Abivax (ABVX), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Its Competitors Organogenesis PureTech Health Kamada Oruka Therapeutics atai Life Sciences Rapport Therapeutics REGENXBIO Erasca Abivax Fulcrum Therapeutics Protalix BioTherapeutics (NYSE:PLX) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Is PLX or ORGO more profitable? Organogenesis has a net margin of -3.46% compared to Protalix BioTherapeutics' net margin of -21.03%. Organogenesis' return on equity of -4.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Organogenesis -3.46%-4.00%-2.26% Which has higher earnings & valuation, PLX or ORGO? Protalix BioTherapeutics has higher earnings, but lower revenue than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$59.76M2.06$8.31M$0.0438.63Organogenesis$482.04M1.14$860K-$0.17-25.59 Do analysts recommend PLX or ORGO? Protalix BioTherapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 870.87%. Organogenesis has a consensus target price of $6.00, suggesting a potential upside of 37.93%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Organogenesis 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in PLX or ORGO? 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 33.0% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor PLX or ORGO? In the previous week, Protalix BioTherapeutics and Protalix BioTherapeutics both had 2 articles in the media. Protalix BioTherapeutics' average media sentiment score of 0.50 beat Organogenesis' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, PLX or ORGO? Protalix BioTherapeutics has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. SummaryProtalix BioTherapeutics beats Organogenesis on 8 of the 15 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$122.99M$202.67M$5.49B$20.63BDividend YieldN/AN/A5.38%3.75%P/E Ratio-11.88N/A27.4228.08Price / Sales2.06223.65407.9745.89Price / Cash17.8022.4436.6322.31Price / Book3.295.618.084.59Net Income$8.31M-$96.61M$3.16B$985.44M7 Day Performance0.32%-0.56%2.81%2.78%1 Month Performance-3.44%-0.93%3.68%5.41%1 Year Performance48.56%16.18%35.29%14.61% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.9618 of 5 stars$1.55+3.0%$15.00+870.9%+45.8%$122.99M$59.76M-11.88200Gap UpORGOOrganogenesis4.1017 of 5 stars$3.34+3.4%$5.50+64.7%+55.9%$423.68M$482.04M-19.65950News CoveragePRTCPureTech Health2.0635 of 5 stars$17.56+0.7%$45.00+156.3%-22.2%$421.79M$4.83M0.00100Gap UpKMDAKamada4.1744 of 5 stars$7.26+0.8%$14.67+102.0%+50.6%$417.52M$160.95M25.03360Positive NewsORKAOruka Therapeutics2.2295 of 5 stars$10.90-6.7%$40.38+270.4%N/A$408.10MN/A-2.42N/ANews CoverageATAIatai Life Sciences3.0262 of 5 stars$2.02-18.5%$8.67+329.0%+116.8%$404.69M$310K-2.2280Analyst ForecastOptions VolumeHigh Trading VolumeRAPPRapport Therapeutics1.3748 of 5 stars$10.88-0.4%$32.67+200.2%-48.3%$397.12MN/A-3.15N/AGap UpRGNXREGENXBIO4.4169 of 5 stars$7.86-6.8%$31.63+302.4%-19.3%$394.26M$83.33M-2.53370ERASErasca3.0943 of 5 stars$1.39+1.5%$4.57+228.9%-36.7%$393.77MN/A-2.24120ABVXAbivax1.7344 of 5 stars$6.11+2.3%$31.00+407.4%-39.0%$387.68MN/A0.0061News CoverageGap UpFULCFulcrum Therapeutics0.3464 of 5 stars$7.17+2.6%$6.29-12.3%+13.8%$387.03M$80M-102.41100 Related Companies and Tools Related Companies Organogenesis Alternatives PureTech Health Alternatives Kamada Alternatives Oruka Therapeutics Alternatives atai Life Sciences Alternatives Rapport Therapeutics Alternatives REGENXBIO Alternatives Erasca Alternatives Abivax Alternatives Fulcrum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
